Genome editing prevents hypertrophic cardiomyopathy in mice

Affiliations

Comment

Gregory B Lim. Nat Rev Cardiol. 2023 Apr.

. 2023 Apr;20(4):211.

doi: 10.1038/s41569-023-00852-8.

No abstract available

Comment on

Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice.
Chai AC, Cui M, Chemello F, Li H, Chen K, Tan W, Atmanli A, McAnally JR, Zhang Y, Xu L, Liu N, Bassel-Duby R, Olson EN. Chai AC, et al. Nat Med. 2023 Feb;29(2):401-411. doi: 10.1038/s41591-022-02176-5. Epub 2023 Feb 16. Nat Med. 2023. PMID: 36797478 Free PMC article.
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice.
Reichart D, Newby GA, Wakimoto H, Lun M, Gorham JM, Curran JJ, Raguram A, DeLaughter DM, Conner DA, Marsiglia JDC, Kohli S, Chmatal L, Page DC, Zabaleta N, Vandenberghe L, Liu DR, Seidman JG, Seidman C. Reichart D, et al. Nat Med. 2023 Feb;29(2):412-421. doi: 10.1038/s41591-022-02190-7. Epub 2023 Feb 16. Nat Med. 2023. PMID: 36797483 Free PMC article.

1. Chai, A. C. et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat. Med. https://doi.org/10.1038/s41591-022-02176-5 (2023) - DOI - PubMed - PMC
1. Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. https://doi.org/10.1038/s41591-022-02190-7 (2023) - DOI - PubMed - PMC

1. Nishiga, M. et al. The use of new CRISPR tools in cardiovascular research and medicine. Nat. Rev. Cardiol. 19, 505–521 (2022) - DOI - PubMed